Kevin J. Gould Sells 13,650 Shares of AngioDynamics, Inc. (NASDAQ:ANGO) Stock

AngioDynamics, Inc. (NASDAQ:ANGO) Director Kevin J. Gould sold 13,650 shares of the firm’s stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $21.45, for a total transaction of $292,792.50. Following the transaction, the director now directly owns 61,774 shares in the company, valued at $1,325,052.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

NASDAQ:ANGO traded down $0.01 during mid-day trading on Thursday, reaching $21.53. The stock had a trading volume of 107,534 shares, compared to its average volume of 219,032. The business has a 50-day simple moving average of $19.85. The stock has a market capitalization of $796.42 million, a PE ratio of 25.94 and a beta of 0.69. The company has a quick ratio of 3.75, a current ratio of 4.30 and a debt-to-equity ratio of 0.20. AngioDynamics, Inc. has a 12 month low of $18.11 and a 12 month high of $25.48.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Wednesday, July 10th. The medical instruments supplier reported $0.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.01). The firm had revenue of $96.30 million during the quarter, compared to the consensus estimate of $92.34 million. AngioDynamics had a net margin of 17.06% and a return on equity of 5.58%. The business’s revenue was up 9.1% compared to the same quarter last year. During the same period last year, the business earned $0.20 earnings per share. Sell-side analysts expect that AngioDynamics, Inc. will post 0.27 earnings per share for the current fiscal year.

A number of large investors have recently made changes to their positions in the stock. Fenimore Asset Management Inc. boosted its position in AngioDynamics by 0.5% in the second quarter. Fenimore Asset Management Inc. now owns 571,100 shares of the medical instruments supplier’s stock valued at $11,245,000 after buying an additional 2,800 shares in the last quarter. Nisa Investment Advisors LLC boosted its position in AngioDynamics by 100.0% in the second quarter. Nisa Investment Advisors LLC now owns 2,200 shares of the medical instruments supplier’s stock valued at $43,000 after buying an additional 1,100 shares in the last quarter. WINTON GROUP Ltd boosted its position in AngioDynamics by 18.7% in the second quarter. WINTON GROUP Ltd now owns 17,669 shares of the medical instruments supplier’s stock valued at $348,000 after buying an additional 2,786 shares in the last quarter. Nordea Investment Management AB boosted its position in AngioDynamics by 1.5% in the first quarter. Nordea Investment Management AB now owns 223,771 shares of the medical instruments supplier’s stock valued at $5,115,000 after buying an additional 3,376 shares in the last quarter. Finally, Kennedy Capital Management Inc. boosted its position in AngioDynamics by 4.2% in the first quarter. Kennedy Capital Management Inc. now owns 357,852 shares of the medical instruments supplier’s stock valued at $8,180,000 after buying an additional 14,448 shares in the last quarter. 98.47% of the stock is currently owned by institutional investors and hedge funds.

ANGO has been the topic of several recent research reports. TheStreet cut shares of Upland Software from a “b-” rating to a “c+” rating in a report on Wednesday, July 10th. ValuEngine cut shares of Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. BidaskClub raised shares of Westport Fuel Systems from a “hold” rating to a “buy” rating in a research note on Friday, July 12th. Finally, Zacks Investment Research raised shares of Investar from a “hold” rating to a “buy” rating and set a $27.00 price objective on the stock in a research note on Tuesday, June 4th. Two analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $21.50.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Recommended Story: What is the LIBOR?

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.